Sarcomas and Malignancies of the Bone
Malignancies of the soft tissues (6%) and bone (5%) account for more than 10% of cancers diagnosed in children, adolescents, and young adults. Benign musculoskeletal neoplasms are one hundred times more common than malignant soft tissue tumors.
- Fibrosarcoma, an aggressive and highly metastatic cancer of the connective tissue, primarily develops in the metaphyses of long tubular bones, and affects both children and adults. The poor prognosis associated with fibrosarcoma can be attributed to both the aggressive metastatic spread characteristic of this cancer and lack of efficacy in current treatment.
- Liposarcoma, a malignancy of fat cells, is the most common soft tissue sarcoma with an annual incidence of 2.5% cases per million.
- Osteosarcoma accounts for about 60% of malignant bone tumors between the ages of 10 to 20. The remaining bone malignancies in children and adolescents are Ewing sarcomas. Ewing sarcomas are histologically similar and identical to peripheral primitive neuroectodermal tumors.
- Chondrosarcomas most often affect older adults.
- Rhabdosarcoma, the most common soft tissue sarcoma is mesenchymal in origin, and affects infants and children up to five years (mostly males).
- Synovial sarcoma, a soft tissue cancer that most often occurs around leg or arm joints, has a 50% rate of metastasis.
We investigated the effect of micronutrient synergy in vitro on human rhabdosarcoma, liposarcoma and chondrosarcoma cell lines and, in vitro and in vivo on human osteosarcoma, synovial sarcoma and fibrosarcoma cell lines. Click here for scientific publications on these topics.
Our results suggest that a micronutrient mixture containing vitamin C, EGCG, Lysine, Proline and other natural components is effective in inhibiting cancer cells proliferation, secretion of MMPs and cancer invasion through Matrigel in vitro and in inhibiting the tumor growth of grafted saracoma cell lines in nude mice.
See publication list